Report Overview

The Global Hereditary angioedema drugs market size stood at USD 2.52 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

The global hereditary angioedema therapeutic market size was valued at USD 2.5 billion in 2018. Growing cases of hereditary angioedema (HAE) globally is a key market driver. According to the National Organization for Rare Disorders (NORD), about 1-9 people per 100,000 population are affected by the condition. The actual number of individuals with the condition are significantly higher due to under-reporting and misdiagnosis

Lack of awareness about HAE is a major reason for misdiagnosis, which in turn, leads to inadequate treatment being provided to patients. Most patients with hereditary angioedema are misdiagnosed for conditions related to appendicitis, gastrointestinal disorders, and other non-allergic angioedema. Significant number of patients being misdiagnosed for the condition has generated a vast patient pool with substantial medical needs. This is likely to be a key driving factor for the market



Market Drivers

Rising initiatives for improving awareness levels among the general population is another factor contributing to the growth of the market. HAE International (HAE I), an international hereditary angioedema patient organization, along with other patient organizations from across the globe lend their support to HAE day, which is marked on May 16thevery year. The aim of the initiative is to facilitate faster diagnosis and provide optimal standards of treatment and care to patients